Al­lied with Genen­tech and Pfiz­er on dis­cov­ery deals, pro­tein degra­da­tion crew at Arv­inas looks for $100M IPO ahead of PhI start

The next wave of biotech IPOs is start­ing to swell to­day as the pro­tein degra­da­tion crew at Arv­inas jumps in with a $100 mil­lion of­fer­ing. And once again we’re see­ing a dis­cov­ery com­pa­ny go­ing ear­ly — with their first Phase I pro­gram still out ahead.

Arv­inas gained a con­sid­er­able amount of at­ten­tion for two deals with Genen­tech and Pfiz­er, which we now know came with a rel­a­tive­ly small up­front and big back end num­bers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.